
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MOLN | Switzerland | CHF | Delayed | |
MOLN | NASDAQ | USD | Real-time |
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners’ first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Steven H. Holtzman | 67 | 2014 | Independent Non Executive Director |
Patrick Amstutz | 46 | 2004 | Co-Founder, CEO, Member of Management Board & Director |
Dominik Hochli | 54 | 2021 | Independent Director |
Agnete B. Fredriksen | 48 | 2021 | Independent Director |
Michael J. Vasconcelles | 58 | 2020 | Independent Director |
Sandip S. Kapadia | 51 | 2020 | Independent Director |
William A. M. Burns | 72 | 2017 | Independent Chairman of the Board |
Vito J. Palombella | 58 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review